Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Caribou Biosciences (CRBU) Current Assets (2020 - 2025)

Caribou Biosciences has reported Current Assets over the past 6 years, most recently at $145.2 million for Q4 2025.

  • Quarterly Current Assets fell 33.8% to $145.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $145.2 million through Dec 2025, down 33.8% year-over-year, with the annual reading at $145.2 million for FY2025, 33.8% down from the prior year.
  • Current Assets was $145.2 million for Q4 2025 at Caribou Biosciences, down from $155.5 million in the prior quarter.
  • Over five years, Current Assets peaked at $449.0 million in Q3 2021 and troughed at $143.0 million in Q2 2021.
  • The 5-year median for Current Assets is $268.5 million (2023), against an average of $274.3 million.
  • Year-over-year, Current Assets skyrocketed 1509.45% in 2021 and then tumbled 35.26% in 2024.
  • A 5-year view of Current Assets shows it stood at $391.2 million in 2021, then crashed by 33.47% to $260.2 million in 2022, then skyrocketed by 30.2% to $338.8 million in 2023, then tumbled by 35.26% to $219.4 million in 2024, then tumbled by 33.8% to $145.2 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's Current Assets are $145.2 million (Q4 2025), $155.5 million (Q3 2025), and $192.5 million (Q2 2025).